One month after acquiring Five Prime Therapeutics and the company’s Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion, Amgen announced that the U.S. Food and Drug Administration awarded Breakthrough Therapy Designation to the asset as a first-line treatment for certain types of gastric cancer.
Relay Therapeutics entered a global license and collaboration agreement with Genentech for the commercialization and development of RLY-1971, a potent inhibitor of SHP2.
Two years after nabbing three novel anti-infective drug candidates from Novartis for the treatment of antibiotic-resistant infections, Boston Pharmaceuticals struck a deal with the Swiss pharma giant for a potential treatment for non-alcoholic steatohepatitis (NASH).
AstraZeneca is significantly expanding the company’s footprint in China with the establishment of a global R&D center and launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.
Johnson & Johnson’s drug Balversa won U.S. approval as the first targeted therapy for advanced bladder cancer, the Food and Drug Administration announced.